178 A Pilot Study of Caregiver's Recall of Their Child's Skin Test Results and Environmental Remediation Education

177 Effect of EPA-DHA Supplementation on Forced Expiratory Volume in One Second (FEV1) and Triglycerides in Obese Adolescents With Hypertriglyceridemia Nancy Mendez Berreondo. 3204, Distrito Federal, Mexico. Background: Evaluate the effect of supplementation of eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA) in FEV1 and triglyceride levels in obese adolescents. Methods: Single blinded, parallel, clinical trial in 2 groups of adolescents supplemented with an intake of 3 gm/d of EPA-DHA versus 3 gm of grenetin for 3 months. We included adolescents with exogenous obesity with Body Mass Index (BMI) CDC . 95%. All patients underwent anthropometry, lipid profile and spirometry at baseline and study end. They were divided into 2 groups: G1: EPA-DHE obese and G2: Grenetin obese. Samples analyzed by T Student (paired and independent). Results: Adolescents were recruited with hypertriglyceridemia . 150 mg/dl, female 45.5%, male 54.5% mean and SD 12 6 1.3 years. There were 34 patients in G1 and G2: 40 patients. The initial values averages the baseline IC 95% FEV1 G1 102.27 (106.06–98.48), G2 102.18 (106.12–98.26), Tiffaneau Index G1: 0.87 (0.90–0.84), G2 0.85 (0.83–0.88) Triglycerides G1 221.71 (246.10–197.32), G2 190.91 (206.90–174.92), Cholesterol G1 169.29 (179.35–159.23), G2 157.09 (169.90–144.28), HDL G1 32.96 (35.58– 30.36), G2 33.85 (36.55–31.06). After 3 months, FEV1 G1 100.39 (104.99–95.79), G2 100.80 (105.88–95.74), Tiffaneau Index G1 0.83 (0.85–0.81), G2 0.86 (0.86–0.83) Triglycerides G1 101.00 (117.64–84.36), G2 127.09 (149.87–104.31), Cholesterol G1 169.88 (181.70–158.06), G2 163.32 (176.00–148.64), HDL G1 35.95 (40.25–31.66), G2 35.81 (38.93– 32.71). Supplementation with EPA-DHA and grenetine for 3 months in triglyceride basal levels had only one significant value (P , 0.05), without a significant in FEV1. Conclusions: Supplementation with EPA-DHA and grenetine for 3 months is helpful for reducing basal levels of triglycerides.